| Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare seizure disorders. Co.'s clinical stage product candidate, ganaxolone, is a positive allosteric modulator of gamma-aminobutyric acid (GABAA) being developed in formulations for two different routes of administration: intravenous (IV) and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. Ganaxolone acts at both synaptic and extrasynaptic GABAA receptors and exhibits anti-seizure, antidepressant and anxiolytic properties. We show 30 historical shares outstanding datapoints in our MRNS shares outstanding history coverage, used to compute MRNS market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MRNS market cap history over the course of time is important for investors
interested in comparing MRNS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MRNS versus a peer is one thing; comparing
MRNS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MRNS can fluctuate over the course of history.
With this page we aim to empower investors researching MRNS by allowing them to research the MRNS market cap history.